Fig. 1. Antituberculosis drug resistance rate (%) and pattern in sanatoria of North Korea: (A) patients (n = 489) in all sanatoria analyzed in this study,

Slides:

Advertisements

Similar presentations

Management of Drug-Resistant Tuberculosis Your name Institution/organization Meeting Date International Standard 12.

Advertisements

Building Global HIV/AIDS Clinical Pharmacology Research Capacity HIV and TB: Capacity Challenges to the use of Current Drugs and Developing New Drugs Kimberly.

TREATMENT OF TUBERCULOSIS, 2003

Second-line Anti-TB drugs

‘Resistant infections’ Dr Julian Sutton Consultant in Infectious Diseases & Medical Microbiology.

Adverse Drug Reactions to Anti-TB drugs Dr M A Jalil Chowdhury Professor of Medicine Bangabandhu Sheikh Mujib Medical University.

1 Constructing a regimen Session 5. USAID TB CARE II PROJECT Principles of designing an MDR-TB treatment regimen Include at least four second-line anti-TB.

Module 3: Drug-Resistant TB. Learning Objectives Describe how drug resistance emerges Explain the difference between primary and secondary resistance.

Antimycobacterial drugs Tuberculosis Treatment of mycobacterial infections is complicated due: Limited information regarding antimycobacterial drug actions.

TB. Areas of Concern TB cases continue to be reported in every state Drug-resistant cases reported in almost every state Estimated million persons.

Clinical Pharmacy.  Tuberculosis is caused by M. tuberculosis, an aerobic, non–spore-forming bacillus that resists decolorization by acid alcohol after.

4 th National Anti-tuberculosis Drug Resistance Survey Botswana, 2007.

Christoph Lange & Giovanni Sotgiu Principles of designing a TB and MDR-TB drug regimen.

Guidelines for chemotherapy of tuberculosis in Taiwan 馬偕紀念醫院一般內科及感染科主治醫師曾祥洸

Vall d’Hebron Servei de Microbiologia External quality assurance for drug susceptibility testing of M. tuberculosis against second line anti-tuberculosis.

Tuberculosis: What you need to know!

Page 1 Extreme Drug Resistant TB and the Work Place Dr Jennifer Coetzee Ampath.

British Society for Microbial Technology The laboratory diagnosis of tuberculosis 25 years of progress D A Mitchison St George’s, University of London.

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc. Chapter 89 Antimycobacterial Agents: Drugs for Tuberculosis, Leprosy,

Extensive Second-line Drug Resistance in Tuberculosis - “XDR TB”: Global Survey of Supranational TB Reference Laboratories Sarita Shah 1, Abigail Wright.

Introduction to Elements of In-Country Drug Management with Focus on TB Drugs Jim Rankin Director, Center for Pharmaceutical Management Management Sciences.

Anri Uys (MSc Pharmacology, BPharm NWU) Medicines Information Centre, Division of Clinical Pharmacology University of Cape Town.

TB 101 Part II Brenda Mayes, R. N. March TREATMENT TB DISEASE MDR XDR LATENT TB INFECTION.

Treatment of Tuberculosis: New Case Case Studies Module 7A2 – March 2010.

Mutant Prevention Concentration and the Selection Window Hypothesis Karl Drlica, Xilin Zhao, and Tao Lu Public Health Research Institute Newark, NJ.

Trials and evidence in relation to health policy: The case of tuberculosis in Nepal and India Ian Harper.

Molecular diagnosis of drug resistant tuberculosis by a DNA array

Unit 11 Drug Resistance and MDR-TB: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.

Acquired Drug Resistance  64 year old female of Hmong ethnicity with long standing, poorly controlled diabetes. No hx TB dx/tx.  11/6/08 CXR “active.

Anti-tuberculosis drugs. First-line drugs Isoniazid (INH or H) Rifampin (RMP or R) Ethambutol (EMB or E) Pyrazinamide (PZA or Z)

Treatment Regimens for Pulmonary Tuberculosis Caused by Drug- Susceptible Organisms Initial PhaseContinuation Phase RegimenDrugs Interval and Doses (Minimal.

TREATMENT OF TUBERCULOSIS: Prevention: BCG vaccination: It does not prevent infection but limits multiplication and spread of following infection so prevents.

항결핵제 감수성시험의 정도관리 2009 년 7 월 3 일 결핵연구원 김창기. 배경 Emergence of resistant tuberculosis –Multidrug-resistant tuberculosis (MDR-TB) Resistant to INH and RIF.

Comprehensive Treatment of Extensively Drug-Resistant Tuberculosis N Engl J Med 2008;359: R2 이 설 라.

Anti-TB Agents Dr. Jeff Hobden MIP. Mycobacterium tuberculosis TB is hard to kill with antibiotics TB is hard to kill with antibiotics Slow growth Slow.

Management of Tuberculosis: A Surgical Perspective

TUBERCULOSIS IN JAPAN ANNUAL REPORT – 2016.

Treatment of TB Disease

Treatment algorithm for tuberculosis

CHM 708 Anti-Bacterial Drugs.

. Antitubercular Drugs.

SUSCEPTIBILITY TESTING OF MYCOBACTERIUM KANSASII STRAINS ISOLATED FROM PATIENTS BETWEEN 2000 AND 2015 IN POLAND Zofia Bakuła1, Magdalena Modrzejewska1,

Treatment algorithm for tuberculosis

1 Drug susceptible TB Limited resistance MDR-TB (Frieden, 1993) XDR-TB

Drug Resistant (DR) TB (Back to Basics)

Ph.D, FMLSCN, FIBMS (Lond)

Part 1 Principles of resistance to antituberculosis drugs

Reduced turn-around time for Mycobacterium tuberculosis drug susceptibility testing with a proportional agar microplate assay V.A.T. Nguyen, H.Q. Nguyen,

Rapid diagnosis of pyrazinamide-resistant multidrug-resistant tuberculosis using a molecular-based diagnostic algorithm S.O. Simons, T. van der Laan,

مقدمه مایکوباکتریوم توبرکلوزیس متعلق به خانواده مایکوباکتریاسه و راسته آکتینومیتالها و مولد بیماری سل می‌باشد. باسیل‌های سل میله‌ای شکل، بلند و خمیده و.

Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries Kathrin Zürcher, Marie Ballif, Lukas Fenner, Sonia.

Richard Laing, Kelly McGoldrick

STREAM (Evaluation of a Standardised Treatment Regimen of Anti-tuberculosis Drugs for Patients with Multidrug-resistant Tuberculosis) treatment regimens.

HSP65-PRA identification of non-tuberculosis mycobacteria from 4892 samples suspicious for mycobacterial infections M. Saifi, E. Jabbarzadeh, A.R. Bahrmand,

Respiratory System Drugs

Bio-AMS enhances the activity of rifampicin and ethambutol in vitro

Characterization of Mycobacterium tuberculosis isolated from cancer patients with suspected tuberculosis infection in Egypt: identification, prevalence,

L. Zhang, Q. Meng, S. Chen, M. Zhang, B. Chen, B. Wu, G. Yan, X

Clinical Epidemiology and Global Health

Anti Tuberculosis Norah A A AL KHATHLAN MD 4/18/2019 Failure or MDR_TB.

Tuberculosis drug-resistance in Lisbon, Portugal: a 6-year overview

CASE HOLDING FOR PMDT.

TUBERCULOSIS Pulmonary TB Drug therapy Dr. Ishfaq Dr. Aliah.

Treatment of Drug Resistant TB - Questions

Fig. 2 Fabrication and in vitro release of TB antibiotics from individual drug pills. Fabrication and in vitro release of TB antibiotics from individual.

DR SAUMU WAYUWA KPA ANNUAL SCIENTIFIC CONFERENCE 2019

Diversity of resistant and susceptible isolates.

Figure 4. Clinical course of patients with disseminated MDR-tuberculosis. MTB, Mycobacterium tuberculosis ; B-MRI, brain MRI; B-CT, brain CT; TB, tuberculosis;

Bio-AMS enhances the activity of rifampicin and ethambutol in vitro

Basic diagnostic algorithm to link the molecular line probe assay with solid culture- and liquid culture-based growth detection and susceptibility testing.

Presentation transcript:

Fig. 1. Antituberculosis drug resistance rate (%) and pattern in sanatoria of North Korea: (A) patients (n = 489) in all sanatoria analyzed in this study, (B) patients (n = 263) in region A, (C) patients (n = 108) in sanatoria located in region B, and (D) patients (n = 118) in region C. M. tuberculosis strains were isolated from the first sputum samples of each patient and used for DST as described in the text. Region A = the capital city area, Region B = North Pyongan Province, Region C = South Pyongan and Hwanghae Provinces, DST = drug susceptibility test, TB = tuberculosis, INH = isoniazid, RIF = rifampicin, EMB = ethambutol, PZA = pyrazinamide, S = streptomycin, Km = kanamycin, Am = amikacin, Cm = capreomycin, Ofx = ofloxacin, Mfx = moxifloxacin, PAS = para-aminosalicylic acid, Eto = ethionamide, Cs = cycloserine. Fig. 1. Antituberculosis drug resistance rate (%) and pattern in sanatoria of North Korea: (A) patients (n = 489) in all sanatoria analyzed in this study, (B) patients (n = 263) in region A, (C) patients (n = 108) in sanatoria located in region B, and (D) patients (n = 118) in region C. M. tuberculosis strains were isolated from the first sputum samples of each… J Korean Med Sci. 2017 Jul;32(7):1105-1110. https://doi.org/10.3346/jkms.2017.32.7.1105